Aurora Cannabis and CTT Pharmaceutical Holdings announced today the launch of CTT's cannabinoid-infused sublingual wafers. The new cannabis product will be sold in the Canadian medical cannabis market under the brand name "Dissolve Strips". Edmonton-based Aurora says it has an ownership interest in CTT of approximately 9 per cent, with a warrant allowing it to increase its stake to 42.5 per cent, and access to CTT's sublingual wafers drug delivery technology, which is patent protected or patent pending in multiple jurisdictions. "The product launch with Aurora of the Dissolve Strips is a major milestone for us that marks the transition of CTT from a technology development phase to a revenue generating phase," Hamilton-based CTT's CEO Cam Birge said.